Radiolabeled Sugars Used for PET and SPECT Imaging

Area of Science:

• Molecular imaging
• Radiopharmaceutical science
• Oncology

Background:

• Radiolabeled carbohydrates serve as vital substrate probes for investigating biological processes in vivo.
• The development of novel "sugar" probes is a key focus in current molecular imaging research for human clinical applications.
• 2-Deoxy-2-[18F]fluoro-D-glucose (18F-FDG) is a prominent example, widely utilized due to its uptake by cancer cells.

Purpose of the Study:

• To review the significance of 18F-FDG and other radiolabeled carbohydrates as imaging probes in PET and SPECT.
• To highlight advancements in molecular imaging driven by these carbohydrate-based probes.
• To explore the potential of novel radiolabeled molecules in cancer diagnosis and therapy.

Main Methods:

• Review of existing literature on radiolabeled carbohydrate probes for molecular imaging.
• Focus on the application and impact of 18F-FDG in Positron Emission Tomography (PET).
• Discussion of the role of these probes in Single Photon Emission Computed Tomography (SPECT) imaging.

Main Results:

• 18F-FDG has significantly advanced human PET imaging, particularly in oncology.
• Radiolabeled sugars are effective substrate probes for studying specific physiological and pathological processes.
• The review underscores the established importance of 18F-FDG and similar probes in clinical imaging.

Conclusions:

• Radiolabeled sugars are indispensable tools in modern molecular imaging, especially PET and SPECT.
• The development of new radiolabeled molecules holds promise for improved cancer detection and targeted therapy.
• Further research into novel radiopharmaceuticals could lead to significant breakthroughs in oncological treatment.